Literature DB >> 16797591

Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.

Benedicto Crespo-Facorro1, José María Pelayo-Terán, Rocío Pérez-Iglesias, Mariluz Ramírez-Bonilla, Obdulia Martínez-García, Gema Pardo-García, José Luis Vázquez-Barquero.   

Abstract

Approximately 60% of patients with a first episode of psychosis will significantly reduce the severity of their positive symptomatology with antipsychotic drugs. The aim of this study was to investigate predictors of response to antipsychotic treatment during the first episode of non-affective psychosis. 172 patients (107 male) with a diagnosis of schizophreniform, schizophrenia, schizoaffective, brief reactive psychosis, schizotypal personality disorder or psychosis non-otherwise specified entered the study. Sociodemographic, premorbid and clinical data at baseline were evaluated. Unpaired t-test for continuous and chi2 for categorical data, respectively, were used to compare responders and non-responders selected variables. Multivariate logistic regression was used to establish a prediction model. 57.6% of study subjects (99 of 172) responded to antipsychotic treatment. The following variables were significantly associated with less likelihood of response: 1.--lower severity of general psychopathology, positive symptoms and disorganized symptoms at baseline; 2.--earlier age of onset; 3.--diagnosis of schizophrenia; 4.--longer DUP; 5.--poorer premorbid adjustment during adolescence, and 6.--hospitalization. Multivariate logistic regression demonstrated that differences between responders and non-responders were largely accounted for by BPRS total score, age of onset, premorbid adjustment at early adolescence, and diagnosis. Patients with an early age of onset of schizophrenia, a poor premorbid adolescent functioning, and with a lower severity of psychopathology at intake seem to have a decrease likelihood of responding to antipsychotic treatment. Helping clinicians to identify non-responders is meant as a first step to optimise therapeutic effort to benefit individuals in this vulnerable group.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16797591     DOI: 10.1016/j.jpsychires.2006.05.002

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  24 in total

Review 1.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

2.  Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.

Authors:  Marie Stentebjerg-Olesen; Stephen J Ganocy; Robert L Findling; Kiki Chang; Melissa P DelBello; John M Kane; Mauricio Tohen; Pia Jeppesen; Christoph U Correll
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-06-02       Impact factor: 4.785

Review 3.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

4.  Aberrant Hippocampal Connectivity in Unmedicated Patients With Schizophrenia and Effects of Antipsychotic Medication: A Longitudinal Resting State Functional MRI Study.

Authors:  Nina Vanessa Kraguljac; David Matthew White; Nathan Hadley; Jennifer Ann Hadley; Lawrence Ver Hoef; Ebony Davis; Adrienne Carol Lahti
Journal:  Schizophr Bull       Date:  2016-02-12       Impact factor: 9.306

5.  Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.

Authors:  Ditte L Vernal; Sandeep Kapoor; Aseel Al-Jadiri; Eva M Sheridan; Yehonathan Borenstein; Charles Mormando; Lisa David; Sukhbir Singh; Andrew J Seidman; Maren Carbon; Miriam Gerstenberg; Ema Saito; John M Kane; Hans-Christoph Steinhausen; Christoph U Correll
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-09       Impact factor: 2.576

6.  A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment.

Authors:  Antonio Drago; Enrico Cocchi; Concetta Crisafulli; Alessandro Serretti
Journal:  J Neural Transm (Vienna)       Date:  2014-07-02       Impact factor: 3.575

7.  Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication.

Authors:  Nathan L Hutcheson; David G Clark; Mark S Bolding; David M White; Adrienne C Lahti
Journal:  Psychiatry Res       Date:  2013-10-22       Impact factor: 3.222

8.  Mental health laws that require dangerousness for involuntary admission may delay the initial treatment of schizophrenia.

Authors:  Matthew M Large; Olav Nielssen; Christopher James Ryan; Robert Hayes
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-11-30       Impact factor: 4.328

9.  Social support, activities, and recovery from serious mental illness: STARS study findings.

Authors:  Michael Hendryx; Carla A Green; Nancy A Perrin
Journal:  J Behav Health Serv Res       Date:  2008-11-15       Impact factor: 1.505

Review 10.  Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics.

Authors:  Pierre Chue; Robin Emsley
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.